Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Protriptyline. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 known ✓ | P23975 | 3/20 | 0.97 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 1.00 |
| ▸ | MEN1 | O00255 | 4/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 4/20 | 1.00 |
| ▸ | PMP22 | Q01453 | 2/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 1.00 |
| ▸ | HTR2A | P28223 | 6/20 | 0.97 |
| ▸ | HRH1 | P35367 | 5/20 | 0.97 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.97 |
| ▸ | CYP2D6 | P10635 | 4/20 | 0.97 |
| ▸ | LMNA | P02545 | 3/20 | 0.97 |
| ▸ | TP53 | P04637 | 3/20 | 0.97 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.97 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.97 |
| ▸ | DRD2 | P14416 | 2/20 | 0.97 |
| ▸ | ADRA2B | P18089 | 2/20 | 0.97 |
| ▸ | ADRA2C | P18825 | 2/20 | 0.97 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.97 |
| ▸ | HTR2C | P28335 | 2/20 | 0.97 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.97 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Protriptyline SCHEMBL5496303 | 1.00 | KDM4E (1.00) | KDM4EMEN1KMT2APMP22SMN1; SMN2 | |
| Protriptyline SCHEMBL2873533 | 1.00 | KDM4E (1.00) | KDM4EMEN1KMT2APMP22SMN1; SMN2 | |
| Protriptyline SCHEMBL29374478 | 0.98 | HTR2A (1.00) | KDM4EMEN1KMT2APMP22SMN1; SMN2 | |
| Protriptyline SCHEMBL34267 | 0.98 | HTR2A (1.00) | KDM4EMEN1KMT2APMP22SMN1; SMN2 | |
| Protriptyline SCHEMBL28105308 | 0.97 | HTR2A (0.97) | KDM4EMEN1KMT2APMP22SMN1; SMN2 | |
| SCHEMBL11838306 | 0.87 | HTR2A (0.80) | KDM4EMEN1KMT2APMP22SMN1; SMN2 | |
| SCHEMBL11720514 | 0.85 | HTR2A (0.76) | KDM4EMEN1KMT2APMP22SMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL11723765 | 0.83 | KDM4E (0.71) | KDM4EMEN1KMT2APMP22SMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL11726955 | 0.82 | KDM4E (0.69) | KDM4EMEN1KMT2APMP22SMN1; SMN2 | |
| SCHEMBL11725316 | 0.81 | HTR2A (0.71) | KDM4EMEN1KMT2APMP22SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 2622 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250152605-A1 | METHOD AND DRUG FOR TREATING NEURONAL CEROID LIPOFUSCINOSIS | TSINGHUA UNIVERSITY (CN) | 2025-05-15 | — | — | US | claimed |
| US-20240307386-A1 | NOVEL METHODS | INTRA-CELLULAR THERAPIES, INC. | 2024-09-19 | — | — | US | claimed |
| EP-4356932-A9 | METHOD AND DRUG FOR TREATING NEURONAL CEROID LIPOFUSCINOSIS | Tsinghua University (CN) | 2024-08-21 | — | — | EP | claimed |
| EP-4356932-A1 | METHOD AND DRUG FOR TREATING NEURONAL CEROID LIPOFUSCINOSIS | Tsinghua University (CN) | 2024-04-24 | — | — | EP | claimed |
| CN-117561083-A | Methods and medicaments for treating neuronal ceroid lipofuscinosis | 清华大学 | 2024-02-13 | — | — | CN | claimed |
| US-20230381168-A1 | ADJUNCTIVE THERAPY FOR DEPRESSION | ANEUROTECH BV (BE) | 2023-11-30 | — | — | US | claimed |
| WO-2022262830-A1 | METHOD AND DRUG FOR TREATING NEURONAL CEROID LIPOFUSCINOSIS | 清华大学 | 2022-12-22 | — | — | WO | claimed |
| CN-115487297-A | Method and medicament for treating neuronal ceroid lipofuscinosis | 清华大学 | 2022-12-20 | — | — | CN | claimed |
| US-20220307034-A1 | INHIBITING APE2 EXPRESSION IN A SUBJECT TREATED WITH A DRUG AGENT THAT CAUSES INCREASED APE2 EXPRESSION | THE CLEVELAND CLINIC FOUNDATION | 2022-09-29 | — | — | US | claimed |
| US-20220050117-A1 | GLX-DERIVED MOLECULE DETECTION | GLX ANALYTIX APS (DK) | 2022-02-17 | — | — | US | claimed |
| WO-2000021504-A1 | ENCAPSULATION OF SENSITIVE LIQUID COMPONENTS INTO A MATRIX TO OBTAIN DISCRETE SHELF-STABLE PARTICLES | GENERAL MILLS, INC. (US) | 2000-04-20 | — | — | WO | claimed |
| EP-0980247-A1 | COMPOSITION AND METHOD COMBINING AN ANTIDEPRESSANT WITH AN NMDA RECEPTOR ANTAGONIST, FOR TREATING NEUROPATHIC PAIN | Algos Pharmaceutical Corporation (US) | 2000-02-23 | — | — | EP | claimed |
| WO-1998050044-A1 | COMPOSITION AND METHOD COMBINING AN ANTIDEPRESSANT WITH AN NMDA RECEPTOR ANTAGONIST, FOR TREATING NEUROPATHIC PAIN | ALGOS PHARMACEUTICAL CORPORATION (US) | 1998-11-12 | — | — | WO | claimed |
| EP-0741570-A1 | METHOD FOR PREVENTING OR REDUCING PHOTOSENSITIVITY AND/OR PHOTOTOXICITY REACTIONS TO MEDICATIONS | G.D. SEARLE & CO. (US) | 1996-11-13 | — | — | EP | claimed |
| EP-0526862-B1 | Solid pharmaceutical compositions for oral administration with prolonged gastric residence | VECTORPHARMA INT (IT) | 1996-02-14 | — | — | EP | claimed |
| WO-1995020387-A1 | METHOD FOR PREVENTING OR REDUCING PHOTOSENSITIVITY AND/OR PHOTOTOXICITY REACTIONS TO MEDICATIONS | G.D. SEARLE & CO. (US) | 1995-08-03 | — | — | WO | claimed |
| EP-0526862-A1 | Solid pharmaceutical compositions for oral administration with prolonged gastric residence | VECTORPHARMA INTERNATIONAL S.p.A. (IT) | 1993-02-10 | — | — | EP | claimed |
| US-4977145-A | ADMINISTERING ANGIOTENSIN CONVERTING ENZYME INHIBITOR AND ANTIDEPRESSANT | E. R. SQUIBB & SONS, INC. (US) | 1990-12-11 | — | — | US | claimed |
| US-4874793-A | Use of protriptyline for the treatment of mental health problems in children | FRANKS DARRELL (US) | 1989-10-17 | — | — | US | claimed |
| EP-0147780-A2 | Drug delivery device | MERCK & CO. INC. (US) | 1985-07-10 | — | — | EP | claimed |